Aspire Private Capital’s Heron Therapeutics HRTX Stock Holding History

Aspire Private Capital’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-300	Closed	-$1K	–	634
2022 Q2	$1K	Hold	300	–	–	﹤0.01%	548
2022 Q1	$2K	Hold	300	–	–	﹤0.01%	496
2021 Q4	$3K	Hold	300	–	–	﹤0.01%	478
2021 Q3	$3K	Hold	300	–	–	﹤0.01%	447
2021 Q2	$5K	Buy	+300	New	+$4.77K	﹤0.01%	388

Other funds holding HRTX

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Aspire Private Capital's HRTX Position: Q3 2022 in Review

Aspire Private Capital sold out of Heron Therapeutics (HRTX) in Q3 2022, closing a stake of 300 shares — an estimated $1K sold.

Aspire Private Capital first reported a position in HRTX in Q2 2021 and held it in 5 quarters. The position peaked at $5K in Q2 2021. 186 funds tracked by Wall St. Rank hold HRTX as of Q3 2022.

Aspire Private Capital reported no remaining Heron Therapeutics position as of Q3 2022 after selling out during the quarter.
Aspire Private Capital sold 300 Heron Therapeutics shares in Q3 2022, an estimated $1K.
Aspire Private Capital first reported a position in Heron Therapeutics in Q2 2021 and held it in 5 quarters.
Aspire Private Capital's Heron Therapeutics position peaked at $5K in Q2 2021.
186 funds tracked by Wall St. Rank held Heron Therapeutics as of Q3 2022.

Based on Aspire Private Capital's 13F filing for Q3 2022, filed 10 Nov 2022.